3rd Microbiome Movement – Drug Development Europe
Recent breakthroughs in DNA sequencing, metagenomic analysis and computational techniques have given scientists new insight into the structure and function of the human microbiota, an interconnected community of symbiotic, commensal and pathogenic microorganisms. As valuable clinical data solidifies the importance of the human microbiome on human health and disease, recent efforts have sought to harness this research to create microbiome-based therapeutics.
Situated at the heart of therapeutic R&D, the Microbiome Movement – Drug Development Summit kick starts 2019, once again to help large pharma, biotech and academic institutions accelerate the discovery, clinical development of safe, effective and commercially scalable microbiome therapeutics across a broad range of disease indications.
Set to tackle the greatest scientific, regulatory, clinical, manufacturing and commercialisation challenges across the entire drug development value chain, this meeting will showcase leading industry case studies focused on enhancing the application of novel technologies to standardise results, accelerate target discovery and optimise the translation of microbiome research into safe and effective therapeutic products.
Early booking and group registration discounts are available upon request. Please visit the website to find out more.